{
    "id": "bowtie_blood_gvhd_v2026_57",
    "type": "bowtie",
    "stem": "A 12-year-old oncology client with severe immunosuppression received a non-irradiated unit of whole blood 10 days ago. He now presents with a diffuse maculopapular rash and jaundice. Based on the documentation in the Post-Transfusion Surveillance tab, complete the bowtie by selecting the most likely condition, the two actions the nurse should take, and the two parameters the nurse should monitor.",
    "itemContext": {
        "tabs": [
            {
                "id": "sbar",
                "title": "SBAR",
                "content": "<b>Situation:</b> Acute multiorgan system failure 10 days post-transfusion. <br><b>Background:</b> Acute Lymphoblastic Leukemia (ALL). Receiving high-dose chemotherapy. <br><b>Assessment:</b> Widespread skin peeling (desquamation) and severe diarrhea. <br><b>Recommendation:</b> Biopsy and marrow check for TA-GVHD."
            },
            {
                "id": "surveillance",
                "title": "Post-Transfusion Surveillance",
                "content": "<table><thead><tr><th>Assessment</th><th>Result</th><th>Interpretation</th></tr></thead><tbody><tr><td>Absolute Neutrophil Count</td><td>150 /mm³ (Critical)</td><td>Pancytopenia</td></tr><tr><td>Liver Enzymes</td><td>AST 342; ALT 410</td><td>Severe Dysfunction</td></tr><tr><td>Skin Exam</td><td>Generalized erythema; Bullae</td><td>Graft attacking host</td></tr><tr><td>Blood Order</td><td>Non-irradiated Whole Blood</td><td>High donor WBC count</td></tr></tbody></table>"
            },
            {
                "id": "vitals",
                "title": "Vital Signs",
                "content": "BP 92/58, HR 132, RR 24, T 103.8°F. Client is in septic-like shock."
            }
        ]
    },
    "bowtieData": {
        "conditionOptions": [
            {
                "id": "c1",
                "text": "Delayed Hemolytic Reaction (Minor Antibody)"
            },
            {
                "id": "c2",
                "text": "Transfusion-Associated Graft vs. Host Disease (TA-GVHD)"
            },
            {
                "id": "c3",
                "text": "Standard Post-Chemotherapy Sepsis"
            }
        ],
        "actionOptions": [
            {
                "id": "a1",
                "text": "Ensure that all future blood products for this client are IRRADIATED"
            },
            {
                "id": "a2",
                "text": "Administer high-dose immunosuppressants and supportive fluid therapy"
            },
            {
                "id": "a3",
                "text": "Increase the IV rate of blood to provide more passive immunity"
            },
            {
                "id": "a4",
                "text": "Administer IV Benadryl to stop the skin rash"
            }
        ],
        "parameterOptions": [
            {
                "id": "p1",
                "text": "Serial CBC with differential (Monitor for Bone Marrow failure)"
            },
            {
                "id": "p2",
                "text": "Liver function tests and total bilirubin levels"
            },
            {
                "id": "p3",
                "text": "Daily measurement of fasting serum glucose"
            },
            {
                "id": "p4",
                "text": "Presence of a positive Trousseau sign"
            }
        ]
    },
    "correctAnswers": {
        "condition": "c2",
        "actions": [
            "a1",
            "a2"
        ],
        "parameters": [
            "p1",
            "p2"
        ]
    },
    "pedagogy": {
        "bloomLevel": "analyze",
        "cjmmStep": "takeAction",
        "nclexCategory": "Physiological Adaptation",
        "difficulty": 5,
        "topicTags": [
            "TA-GVHD",
            "Blood Transfusion",
            "Oncology"
        ]
    },
    "rationale": {
        "correct": "This is Transfusion-Associated Graft vs. Host Disease (TA-GVHD) (c2). It is a rare, usually fatal complication occurring 1-2 weeks post-transfusion when donor T-lymphocytes attack the immunocompromised host's tissues (Skin, Liver, Bone Marrow). The hallmark signs are a rash, liver failure, and severe marrow suppression (Pancytopenia). Priority actions: Ensure all future products are IRRADIATED (a1) to kill donor WBCs and support the patient with aggressive therapy (a2). Key parameters: Bone marrow function (p1) and liver function (p2).",
        "clinicalPearls": [
            "TA-GVHD has a > 90% mortality rate because it wipes out the patient's bone marrow.",
            "The only way to prevent it is IRRADIATION, which uses Gamma rays to neutralize the donor lymphocytes.",
            "Suspect this in oncology patients who 'get sick' 10 days after a blood transfusion."
        ],
        "questionTrap": {
            "trap": "Calling this an 'allergic reaction' because of the rash.",
            "howToOvercome": "Allergic reactions happen during or immediately after the infusion. If it happens 10 days later and involves the liver and bone marrow, it's TA-GVHD."
        },
        "mnemonic": {
            "title": "G-V-H",
            "expansion": "G-Generalized rash. V-Vital organs (Liver) fail. H-Hematologic (Marrow) failure."
        }
    },
    "scoring": {
        "method": "polytomous",
        "maxPoints": 5
    },
    "sentinelStatus": "healed_v2026_v9"
}